Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IPH5201 · 1 trial · 1 indication
Number of patients with pathological Complete Response (pCR)
Number of patients with adverse events (AEs) and serious adverse events (SAEs).
| Arm | Type | Description |
|---|---|---|
| IPH5201 + durvalumab + standard chemotherapy | EXPERIMENTAL | Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy. In Cohort 1 only, following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab. |
| Name | Type | Description |
|---|---|---|
| IPH5201 + durvalumab + standard chemotherapy | DRUG | Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy. In Cohort 1 only, Following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab. |
Inclusion criteria Patients are eligible to be included in the study only if all of the following criteria apply: 1. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and in this protocol. 2. Provis...
Top 20 of 83 competitors
IPH5201 + durvalumab + standard chemotherapy is an investigational combination being studied for the treatment of resectable Non-Small Cell Lung Cancer (NSCLC). It is currently in a Phase 2 clinical trial. The combination is not yet approved and remains under clinical investigation.
IPH5201 targets CD39, an enzyme involved in the tumor microenvironment. By inhibiting CD39, the drug aims to modulate immune responses against cancer cells. It is being studied in combination with durvalumab and standard chemotherapy for Non-Small Cell Lung Cancer.
Innate Pharma S.A. (ticker: IPHA) is developing IPH5201 as part of the combination with durvalumab and standard chemotherapy. The therapy is being evaluated in a Phase 2 clinical trial for patients with resectable Non-Small Cell Lung Cancer.
IPH5201 + durvalumab + standard chemotherapy is in Phase 2 clinical development. It is an investigational combination and has not been approved by regulatory authorities. The ongoing trial is actively recruiting participants.
IPH5201 + durvalumab + standard chemotherapy is being studied in the MATISSE trial (NCT05742607), a Phase 2 study in patients with resectable Non-Small Cell Lung Cancer. The trial is recruiting 70 participants across the United States, France, Greece, Hungary, and Poland.
Yes, IPH5201 + durvalumab + standard chemotherapy is also known as IPH5201 + durvalumab + standard chemotherapy. The combination is being evaluated in the MATISSE trial (NCT05742607) for resectable Non-Small Cell Lung Cancer.